Spark Biomedical
Spark Biomedical is dedicated to transforming healthcare through innovative, drug-free, wearable neurostimulation technology. Their mission is to develop science-backed solutions that address critical needs in mental health, women’s health, hemostasis, and pediatrics, aiming to improve patient outcomes and build a healthier future. They focus on providing safe, effective, non-invasive bioelectronic medicine that fills treatment gaps and offers new treatment paths.
Industries
Nr. of Employees
small (1-50)
Spark Biomedical
Patents
Products
FDA‑cleared wearable auricular neurostimulation system for opioid withdrawal
A market‑cleared wearable auricular neurostimulation system intended to provide non‑pharmacologic symptom relief for patients experiencing opioid withdrawal.
Wearable neonatal auricular neurostimulation device (in clinical evaluation)
A compact, gentle wearable neurostimulation device designed for neonatal use to reduce symptoms associated with neonatal opioid withdrawal; currently under clinical evaluation and subject to regulatory breakthrough designation processes.
Sparrow Ascent
A transcutaneous nerve field stimulator intended to be used in patients experiencing opioid withdrawal in conjunction with standard symptomatic medication and other therapies under the supervision of trained clinical personnel.
Sparrow Ascent Right Earpiece – Model 211
Disposable right earpiece used to deliver transcutaneous auricular neurostimulation.
Sparrow Ascent Left Earpiece – Model 210
Disposable left earpiece used to deliver transcutaneous auricular neurostimulation.
Sparrow Ascent Patient Controller – Model 110
Hand-held, battery-powered patient controller designed to deliver stimulation to the earpiece via a removable cable.
FDA‑cleared wearable auricular neurostimulation system for opioid withdrawal
A market‑cleared wearable auricular neurostimulation system intended to provide non‑pharmacologic symptom relief for patients experiencing opioid withdrawal.
Wearable neonatal auricular neurostimulation device (in clinical evaluation)
A compact, gentle wearable neurostimulation device designed for neonatal use to reduce symptoms associated with neonatal opioid withdrawal; currently under clinical evaluation and subject to regulatory breakthrough designation processes.
Sparrow Ascent
A transcutaneous nerve field stimulator intended to be used in patients experiencing opioid withdrawal in conjunction with standard symptomatic medication and other therapies under the supervision of trained clinical personnel.
Sparrow Ascent Right Earpiece – Model 211
Disposable right earpiece used to deliver transcutaneous auricular neurostimulation.
Sparrow Ascent Left Earpiece – Model 210
Disposable left earpiece used to deliver transcutaneous auricular neurostimulation.
Sparrow Ascent Patient Controller – Model 110
Hand-held, battery-powered patient controller designed to deliver stimulation to the earpiece via a removable cable.
Services
Partnership and operational support for investigator‑led and sponsor trials deploying wearable neurostimulation, including trial design, site partnerships, and device provisioning.
Provision of investigator‑facing tools and services to integrate wearable neurostimulation devices into clinical research workflows.
Partnership and operational support for investigator‑led and sponsor trials deploying wearable neurostimulation, including trial design, site partnerships, and device provisioning.
Provision of investigator‑facing tools and services to integrate wearable neurostimulation devices into clinical research workflows.
Expertise Areas
- Wearable neurostimulation development
- Clinical trial management and design (including decentralized and sham‑controlled trials)
- Hemostasis therapy research and development
- Neonatal neuromodulation for withdrawal syndromes
Key Technologies
- Transcutaneous auricular neurostimulation (tAN)
- Vagus nerve stimulation (VNS)
- Trigeminal nerve stimulation
- Wearable medical device design
News & Updates
The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
New Health Canada Approval Allows Spark Biomedical to Offer Drug-Free Opioid Withdrawal Relief Across Canada.
Details not provided in the source.
Details not provided in the source.
Details not provided in the source.
The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
New Health Canada Approval Allows Spark Biomedical to Offer Drug-Free Opioid Withdrawal Relief Across Canada.
Details not provided in the source.
Details not provided in the source.
Details not provided in the source.